Wound-induced XXXX and its pharmacologic inhibition in a @entity19 model.

@entity5 @entity19 @entity21926 @entity7499
BACKGROUND: A novel synthetic compound, @entity21926 , inhibits subcutaneous @entity5 growth of cells. Because @entity7499 in @entity5 growth and wound healing involves similar mechanisms, we examined whether @entity21926 inhibits wound-induced @entity7499 . METHODS: Sixteen female BALB/c @entity19 were randomized to receive either @entity21926 (n = 8) or vehicle alone (n = 8) on day -2. On day 0, transparent window chambers were implanted into the dorsal skin flap. Treatment was stopped on day 7. On days 1, 7, and 14, micrographs of the windows were taken and microvessel density was estimated. RESULTS: On day 1, no statistically significant difference was noted between the microvessel density in controls and treatments. After the @entity19 underwent treatment from day -2 to day 7 and microvessel densities were analyzed on day 7, @entity7499 was significantly inhibited in the @entity21926 group (P <.001). Seven days after cessation of treatment, however, the @entity21926 group showed complete recovery in @entity7499 . The increase in microvessel density in the @entity21926 group on day 14 from day 7 was not significantly different from that of the control group (P >.05). CONCLUSIONS: We observed that @entity21926 , a known inhibitor of @entity5 -induced @entity7499 , also inhibited wound-induced @entity7499 in our @entity19 wound model. This inhibitory effect is significant while the @entity19 are undergoing treatment.
